223.6

+3.09%↑

MRK1

153.55

-0.71%↓

SHL.DE

48.11

-0.35%↓

UCB

178.7

-0.97%↓

ARGX

544.2

-1.13%↓

223.6

+3.09%↑

MRK1

153.55

-0.71%↓

SHL.DE

48.11

-0.35%↓

UCB

178.7

-0.97%↓

ARGX

544.2

-1.13%↓

223.6

+3.09%↑

MRK1

153.55

-0.71%↓

SHL.DE

48.11

-0.35%↓

UCB

178.7

-0.97%↓

ARGX

544.2

-1.13%↓

223.6

+3.09%↑

MRK1

153.55

-0.71%↓

SHL.DE

48.11

-0.35%↓

UCB

178.7

-0.97%↓

ARGX

544.2

-1.13%↓

223.6

+3.09%↑

MRK1

153.55

-0.71%↓

SHL.DE

48.11

-0.35%↓

UCB

178.7

-0.97%↓

ARGX

544.2

-1.13%↓

Strona główna・Stock List・Sanofi SA

Sanofi SA

Closed

Sector Healthcare

97.74 -0.91

Buy Sell

Overview

Share price change

24h

Current

Min

97.6

Max

99.11

Key metrics
By Trading Economics
Income	1.7B 2.8B
Sales	2.1B 13B
P/E Sector Avg	30.62 104.138
EPS	2.86
Profit margin	20.945
EBITDA	2.2B 4.2B

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+13.81 upside

Dividends
By Dow Jones
Next Earnings	30 sty 2025

Market Stats
By TradingEconomics
Market Cap	123B
Previous open	98.65
Previous close	97.74

News Sentiment

By Acuity

58%

42%

313 / 390 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

98.41 / 99.5 Support & Resistance

Sanofi SA Chart

Past performance is not a reliable indicator of future results.

Related News

29 paź 2024, 10:07 UTC

Earnings

Santander's Profit Beats Expectations on Lower Provisions, Costs -- Update

29 paź 2024, 06:37 UTC

Earnings

Santander's Profit Beats View Despite Lower-Than-Expected Revenue

28 paź 2024, 16:07 UTC

Acquisitions, Mergers, Takeovers

AbbVie to Acquire Aliada Therapeutics for $1.4 Billion -- Update

25 paź 2024, 05:44 UTC

Earnings

Sanofi Profit, Sales Beat Estimates

29 paź 2024, 13:16 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Conditions Lack for Attractive European Cross-Border M&A Deals, Santander CEO Says -- Market Talk

29 paź 2024, 07:02 UTC

Market Talk

Santander's Take on Brazil Rates, Motor-Finance Issue in Focus -- Market Talk

29 paź 2024, 05:52 UTC

Earnings

Santander Backs 2024 View

29 paź 2024, 05:52 UTC

Earnings

Santander: If All Targets Are Met, Total Remuneration Against 2024 Results Over EUR6B

29 paź 2024, 05:51 UTC

Earnings

Santander Confident on Delivering on Targets

29 paź 2024, 05:50 UTC

Earnings

Analysts Saw Santander End-3Q Fully Loaded CET1 Ratio 12.5%

29 paź 2024, 05:50 UTC

Earnings

Santander End-3Q Fully Loaded CET1 Ratio 12.5%

29 paź 2024, 05:49 UTC

Earnings

Analyst Saw Santander 3Q Net Interest Income EUR11.59B

29 paź 2024, 05:49 UTC

Earnings

Santander 3Q Net Interest Income EUR11.225B

29 paź 2024, 05:48 UTC

Earnings

Analysts Saw Santander 3Q Net Loan Loss Provisions EUR3.17B

29 paź 2024, 05:48 UTC

Earnings

Santander 3Q Net Loan Loss Provisions EUR2.98B

29 paź 2024, 05:48 UTC

Earnings

Analysts Saw Santander 3Q Net Pft EUR3.17B

29 paź 2024, 05:48 UTC

Earnings

Santander 3Q Net Pft EUR3.25B

29 paź 2024, 05:48 UTC

Earnings

Santander 3Q Rev EUR15.135B

29 paź 2024, 05:48 UTC

Earnings

Analysts Saw Santander 3Q Rev EUR15.31B

28 paź 2024, 08:18 UTC

Market Talk

Banks' Risks From U.K. Motor Finance Probe Rise -- Market Talk

25 paź 2024, 20:25 UTC

Earnings

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

25 paź 2024, 13:12 UTC

Earnings

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

25 paź 2024, 07:00 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

Sanofi's 3Q Results Show Solid Vaccine Performance -- Market Talk

25 paź 2024, 05:30 UTC

Earnings

Sanofi 3Q Adj EPS EUR2.86

25 paź 2024, 05:30 UTC

Earnings

Sanofi 3Q FCF EUR3.33B

25 paź 2024, 05:30 UTC

Earnings

Analysts Saw Sanofi 3Q Business Operating Income at EUR4.03B

25 paź 2024, 05:30 UTC

Earnings

Sanofi 3Q Business Net Profit EUR3.59B

25 paź 2024, 05:30 UTC

Earnings

Sanofi 3Q Sales EUR13.44B

25 paź 2024, 05:30 UTC

Earnings

Analysts Saw Sanofi 3Q Sales at EUR12.63B

25 paź 2024, 05:30 UTC

Earnings

Sanofi 3Q Business Operating Profit EUR4.61B

Peer Comparison

Price change

Sanofi SA Forecast

Price Target

By TipRanks

13.81% upside

12 Months Forecast

Average 112.331 EUR 13.81%

High 130 EUR

Low 90 EUR

Based on 13 Wall Street analysts offering 12 month price targets forSanofi SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

13 ratings

Buy

Hold

Sell

Based on 13 analysts giving stock ratings to Sanofi SA - Dist in the past 3 months.

Technical Score

By Trading Central

98.41 / 99.5Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

313 / 390 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Sanofi SA

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.